TABLE 3.

The prognostic impacts of metastatic sites on patients with primary malignant cardiac tumors.

	OS		CSS
Variable	HR (95% CI)	P value	HR (95% CI)	P value
Unadjusted HR
Metastasis site		0.75		0.63
Bone	Reference		Reference
Brain	1.72 (0.62–4.77)	0.29	1.96 (0.69–5.53)	0.21
Liver	1.12 (0.47–2.70)	0.79	1.13 (0.45–2.86)	0.79
Lung	1.26 (0.62–2.58)	0.53	1.27 (0.60–2.70)	0.54
Model 1*
Metastasis site		0.24		0.19
Bone	Reference		Reference
Brain	3.20 (1.02–10.00)	0.046	3.53 (1.09–11.47)	0.036
Liver	1.34 (0.53–3.42)	0.53	1.30 (0.49–3.45)	0.60
Lung	1.67 (0.75–3.71)	0.21	1.60 (0.69–3.72)	0.27
Model 2 †
Metastasis site		0.24		0.20
Bone	Reference		Reference
Brain	3.23 (1.01–10.28)	0.047	3.53 (1.07–11.69)	0.039
Liver	1.36 (0.52–3.56)	0.53	1.30 (0.47–3.56)	0.62
Lung	1.69 (0.74–3.87)	0.21	1.60 (0.67–3.83)	0.29
Model 3‡
Metastasis site		0.23		0.21
Bone	Reference		Reference
Brain	3.30 (1.03–10.60)	0.045	3.52 (1.05–11.75)	0.041
Liver	1.37 (0.52–3.57)	0.52	1.30 (0.47–3.56)	0.62
Lung	1.67 (0.73–3.82)	0.23	1.60 (0.67–3.85)	0.29

*HR were adjusted for age at diagnosis, median household income, histopathology, and size.

^†HR were adjusted for age at diagnosis, median household income, histopathology, size, and sex.

^‡HR were adjusted forage at diagnosis, median household income, histopathology, size, sex, and surgery.

OS, overall survival; CSS, cancer specific survival; HR, hazard ratio; CI, confidence interval.